DUKE UNIVERSITY MEDICAL CENTER

CURRICULUM VITAE

for

Permanent Record

and the

Appointments and Promotions Committee

 Date Prepared: 08/18/25

 (Use continuation pages when necessary.)

 Name (complete with degrees): Trudy Gale Oliver, PhD (she/her/hers)

 Primary academic appointment: Professor (with Tenure)

 Primary academic department (not DUAP): Dept of Pharmacology & Cancer Biology

Secondary appointment (if any) - (department):

 Present academic rank and title (if any): Duke Science & Technology Scholar

Date and rank of first Duke Faculty appointment: July 1, 2022

 Medical Licensure: North Carolina License # \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Date of License (Month/Day/Year): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

 Specialty certification(s) and dates (Month/Day/Year): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

 \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

 Date of birth: 12/06/1978 Place (include city/state/country): Lawton, OK

 Citizen of: USA

 Visa status (if applicable): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

 **Education:** Institution Date (Year) Degree

High School Lakewood High School, Lakewood, CO 1997 HS Diploma

College Oklahoma Baptist University 1997-2001 B.S. (Summa Cum

(Chemistry) Shawnee, OK Laude)

Graduate or Duke University 2001-2005 PhD

 Professional (Pharmacology and Cancer Biology) Durham, NC

 School Thesis Title: *Sonic Hedgehog Signaling in Cerebellar Development and Tumorigenesis*

University of North Carolina-Chapel Hill 2005-2006 Visiting Postdoctoral

 (Cancer Biology) Chapel Hill, NC Research Fellow,

Terry Van Dyke Lab

 Massachusetts Institute of Technology 2006-2011 Postdoctoral Fellow

 (Cancer Biology) Cambridge, MA Tyler Jacks Lab

 **Professional training and academic career (chronologically, beginning with first postgraduate position):**

 Institution Position/Title Dates

 University of Utah, Dept of Oncological Sciences Assistant Professor 2011 - 2017

 Huntsman Cancer Institute Investigator 2011 - 2022

 University of Utah, Dept of Oncological Sciences Associate Professor with Tenure 2017 - 2022

 Huntsman Cancer Institute Endowed Chair in Cancer Research 2018 - 2022

 University of Utah, Dept of Oncological Sciences Adjunct Professor 2022 - 2024

 Duke University, Dept of Pharmacology & Professor (Tenure)/ 2022 - present

 Cancer Biology DST Scholar

**Publications:** (Do not include submitted papers or papers in preparation:

List separately those papers in press.) PLEASE NUMBER ALL ENTRIES SEQUENTIALLY (1# OLDEST, Label with PUB Med ID)

Do not use et al. List all authors in the publication

Author name must be bolded,

Date of the journal is required.

1. Refereed journals: (Refereed journals are scientific publications that have active editorial boards

 and a system of critical review of all submissions for publication.)

* + 1. Named author
		2. Study Group publications (Multicenter trials that you were PI but not author)
		3. Letters
		4. Editorials
1. **Oliver TG**, Grasfeder LL, Carroll AL, Kaiser C, Gillingham CL, Lin SM, Wickramasinghe R, Scott MP, Wechsler-Reya RJ (2003). Transcriptional profiling of the Sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors. *Proc Natl Acad Sci U S A*, *100*(12), 7331-6. PubMed PMID: 12777630; PubMed Central PMCID: PMC165875.
2. **Oliver TG**, Wechsler-Reya RJ (2004). Getting at the root and stem of brain tumors. *Neuron*, *42*(6), 885-8. PubMed PMID: 15207233.
3. **Oliver TG**, Read TA, Kessler JD, Mehmeti A, Wells JF, Huynh TT, Lin SM, Wechsler-Reya RJ (2005). Loss of patched and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma. *Development*, *132*(10), 2425-39. PubMed PMID: 15843415.
4. Fogarty MP, Emmenegger BA, Grasfeder LL, **Oliver TG**, Wechsler-Reya RJ (2007). Fibroblast growth factor blocks Sonic hedgehog signaling in neuronal precursors and tumor cells. *Proc Natl Acad Sci U S A*, *104*(8), 2973-8. PubMed PMID: 17299056; PubMed Central PMCID: PMC1815291.
5. Schliekelman M, Cowley DO, O'Quinn R, **Oliver TG**, Lu L, Salmon ED, Van Dyke T (2009). Impaired Bub1 function in vivo compromises tension-dependent checkpoint function leading to aneuploidy and tumorigenesis. *Cancer Res*, *69*(1), 45-54. PubMed PMID: 19117986; PubMed Central PMCID: PMC4770788.
6. Cowley DO, Rivera-Pérez JA, Schliekelman M, He YJ, **Oliver TG**, Lu L, O'Quinn R, Salmon ED, Magnuson T, Van Dyke T (2009). Aurora-A kinase is essential for bipolar spindle formation and early development. *Mol Cell Biol*, *29*(4), 1059-71. PubMed PMID: 19075002; PubMed Central PMCID: PMC2643803.
7. **Oliver TG**, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, Cheng MH, Subramanian A, Mu D, Powers S, Crowley D, Bronson RT, Whittaker CA, Bhutkar A, Lippard SJ, Golub T, Thomale J, Jacks T, Sweet-Cordero EA (2010). Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. *Genes Dev*, *24*(8), 837-52. PubMed PMID: 20395368; PubMed Central PMCID: PMC2854397.
8. Doles J, **Oliver TG**, Cameron ER, Hsu G, Jacks T, Walker GC, Hemann MT (2010). Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. *Proc Natl Acad Sci U S A*, *107*(48), 20786-91. PubMed PMID: 21068376; PubMed Central PMCID: PMC2996428.
9. **Oliver TG**, Meylan E, Chang GP, Xue W, Burke JR, Humpton TJ, Hubbard D, Bhutkar A, Jacks T (2011). Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop. *Mol Cell*, *43*(1), 57-71. PubMed PMID: 21726810; PubMed Central PMCID: PMC3160283.
10. Xue W, Meylan E, **Oliver TG**, Feldser DM, Winslow MM, Bronson R, Jacks T (2011). Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. *Cancer Discov*, *1*(3), 236-47. PubMed PMID: 21874163; PubMed Central PMCID: PMC3160630.
11. Curry NL, Mino-Kenudson M, **Oliver TG**, Yilmaz OH, Yilmaz VO, Moon JY, Jacks T, Sabatini DM, Kalaany NY (2013). Pten-null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary restriction. *Cancer Discov*, *3*(8), 908-21. PubMed PMID: 23719831; PubMed Central PMCID: PMC3743121.
12. Mukhopadhyay A, Berrett KC, Kc U, Clair PM, Pop SM, Carr SR, Witt BL, **Oliver TG** (2014). Sox2 cooperates with Lkb1 loss in a mouse model of squamous cell lung cancer. *Cell Rep*, *8*(1), 40-9. PubMed PMID: 24953650; PubMed Central PMCID: PMC4410849.
13. Masin M, Vazquez J, Rossi S, Groeneveld S, Samson N, Schwalie PC, Deplancke B, Frawley LE, Gouttenoire J, Moradpour D, **Oliver TG**, Meylan E (2014). GLUT3 is induced during epithelial-mesenchymal transition and promotes tumor cell proliferation in non-small cell lung cancer. *Cancer Metab*, *2*, 11. PubMed PMID: 25097756; PubMed Central PMCID: PMC4122054.
14. Mukhopadhyay A, **Oliver TG** (2015). Mighty mouse breakthroughs: a Sox2-driven model for squamous cell lung cancer. *Mol Cell Oncol*, *2*(2), e969651. PubMed PMID: 27308419; PubMed Central PMCID: PMC4904963.
15. **Oliver TG**, Patel J, Akerley W (2015). Squamous non-small cell lung cancer as a distinct clinical entity. *Am J Clin Oncol*, *38*(2), 220-6. PubMed PMID: 25806712.
16. Terry MR, Arya R, Mukhopadhyay A, Berrett KC, Clair PM, Witt B, Salama ME, Bhutkar A, **Oliver TG** (2015). Caspase-2 impacts lung tumorigenesis and chemotherapy response in vivo. *Cell Death Differ, 22*(5), 719-30. PubMed PMID: 25301067; PubMed Central PMCID: PMC4392070.
17. Mollaoglu G, Guthrie MR, Böhm S, Brägelmann J, Can I, Ballieu PM, Marx A, George J, Heinen C, Chalishazar MD, Cheng H, Ireland AS, Denning KE, Mukhopadhyay A, Vahrenkamp JM, Berrett KC, Mosbruger TL, Wang J, Kohan JL, Salama ME, Witt BL, Peifer M, Thomas RK, Gertz J, Johnson JE, Gazdar AF, Wechsler-Reya RJ, Sos ML, **Oliver TG** (2017). MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. *Cancer Cell*, *31*(2), 270-285. PubMed PMID: 28089889; PubMed Central PMCID: PMC5310991. (Selected as *Best of Cancer Cell*, 2017)
18. Brägelmann J, Böhm S, Guthrie MR, Mollaoglu G, **Oliver TG**, Sos ML (2017). Family matters: How MYC family oncogenes impact small cell lung cancer. *Cell Cycle*, *16*(16), 1489-1498. PubMed PMID: 28737478; PubMed Central PMCID: PMC5584863.
19. Cardnell RJ, Li L, Sen T, Bara R, Tong P, Fujimoto J, Ireland AS, Guthrie MR, Bheddah S, Banerjee U, Kalu NN, Fan YH, Dylla SJ, Johnson FM, Wistuba II, **Oliver TG**, Heymach JV, Glisson BS, Wang J, Byers LA (2017). Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. *Oncotarget*, *8*(43), 73419-73432. PubMed PMID: 29088717; PubMed Central PMCID: PMC5650272.
20. Zhang W, Girard L, Zhang YA, Haruki T, Papari-Zareei M, Stastny V, Ghayee HK, Pacak K, **Oliver TG**, Minna JD, Gazdar AF (2018). Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. *Transl Lung Cancer Res*, *7*(1), 32-49. PubMed PMID: 29535911; PubMed Central PMCID: PMC5835590.
21. Huang F, Ni M, Chalishazar MD, Huffman KE, Kim J, Cai L, Shi X, Cai F, Zacharias LG, Ireland AS, Li K, Gu W, Kaushik AK, Liu X, Gazdar AF, **Oliver TG**, Minna JD, Hu Z, DeBerardinis RJ (2018). Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers. *Cell Metab*, *28*(3), 369-382.e5. PubMed PMID: 30043754; PubMed Central PMCID: PMC6125205.
22. Wagner AH, Devarakonda S, Skidmore ZL, Krysiak K, Ramu A, Trani L, Kunisaki J, Masood A, Waqar SN, Spies NC, Morgensztern D, Waligorski J, Ponce J, Fulton RS, Maggi LB Jr, Weber JD, Watson MA, O'Conor CJ, Ritter JH, Olsen RR, Cheng H, Mukhopadhyay A, Can I, Cessna MH, **Oliver TG**, Mardis ER, Wilson RK, Griffith M, Griffith OL, Govindan R (2018). Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. *Nat Commun*, *9*(1), 3787. PubMed PMID: 30224629; PubMed Central PMCID: PMC6141466.
23. Mollaoglu G, Jones A, Wait SJ, Mukhopadhyay A, Jeong S, Arya R, Camolotto SA, Mosbruger TL, Stubben CJ, Conley CJ, Bhutkar A, Vahrenkamp JM, Berrett KC, Cessna MH, Lane TE, Witt BL, Salama ME, Gertz J, Jones KB, Snyder EL, **Oliver TG** (2018). The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment. *Immunity*, *49*(4), 764-779.e9. PubMed PMID: 30332632; PubMed Central PMCID: PMC6197489. (Featured on the Cover)
24. Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV, Johnson JE, Lehman JM, MacPherson D, Massion PP, Minna JD, **Oliver TG**, Quaranta V, Sage J, Thomas RK, Vakoc CR, Gazdar AF (2019). Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. *Nat Rev Cancer*, *19*(5), 289-297. PubMed PMID: 30926931; PubMed Central PMCID: PMC6538259.
25. Guo B, **Oliver TG** (2019). Partners in Crime: Neutrophil-CTC Collusion in Metastasis. *Trends Immunol*, *40*(7), 556-559. PubMed PMID: 31101536; PubMed Central PMCID: PMC6759362.
26. Dammert MA, Brägelmann J, Olsen RR, Böhm S, Monhasery N, Whitney CP, Chalishazar MD, Tumbrink HL, Guthrie MR, Klein S, Ireland AS, Ryan J, Schmitt A, Marx A, Ozretić L, Castiglione R, Lorenz C, Jachimowicz RD, Wolf E, Thomas RK, Poirier JT, Büttner R, Sen T, Byers LA, Reinhardt HC, Letai A, **Oliver TG**, Sos ML (2019). MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. *Nat Commun*, *10*(1), 3485. PubMed PMID: 31375684; PubMed Central PMCID: PMC6677768.
27. Chalishazar MD, Wait SJ, Huang F, Ireland AS, Mukhopadhyay A, Lee Y, Schuman SS, Guthrie MR, Berrett KC, Vahrenkamp JM, Hu Z, Kudla M, Modzelewska K, Wang G, Ingolia NT, Gertz J, Lum DH, Cosulich SC, Bomalaski JS, DeBerardinis RJ, **Oliver TG** (2019). MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion. *Clin Cancer Res*, *25*(16), 5107-5121. PubMed PMID: 31164374; PubMed Central PMCID: PMC6697617.
28. Cable J, Finley L, Tu BP, Patti GJ, **Oliver TG**, Vardhana S, Mana M, Ericksen R, Khare S, DeBerardinis R, Stockwell BR, Edinger A, Haigis M, Kaelin W (2020). Leveraging insights into cancer metabolism-a symposium report. *Ann N Y Acad Sci*, *1462*(1), 5-13. PubMed PMID: 31792987; PubMed Central PMCID: PMC7255687.
29. Poirier JT, George J, Owonikoko TK, Berns A, Brambilla E, Byers LA, Carbone D, Chen HJ, Christensen CL, Dive C, Farago AF, Govindan R, Hann C, Hellmann MD, Horn L, Johnson JE, Ju YS, Kang S, Krasnow M, Lee J, Lee SH, Lehman J, Lok B, Lovly C, MacPherson D, McFadden D, Minna J, Oser M, Park K, Park KS, Pommier Y, Quaranta V, Ready N, Sage J, Scagliotti G, Sos ML, Sutherland KD, Travis WD, Vakoc CR, Wait SJ, Wistuba I, Wong KK, Zhang H, Daigneault J, Wiens J, Rudin CM, **Oliver TG** (2020). New Approaches to SCLC Therapy: From the Laboratory to the Clinic. *J Thorac Oncol*, *15*(4), 520-540. PubMed PMID: 32018053; PubMed Central PMCID: PMC7263769.
30. Stewart CA, Gay CM, Xi Y, Sivajothi S, Sivakamasundari V, Fujimoto J, Bolisetty M, Hartsfield PM, Balasubramaniyan V, Chalishazar MD, Moran C, Kalhor N, Stewart J, Tran H, Swisher SG, Roth JA, Zhang J, de Groot J, Glisson B, **Oliver TG**, Heymach JV, Wistuba I, Robson P, Wang J, Byers LA (2020). Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. *Nat Cancer*, *1*, 423-436. PubMed PMID: 33521652; PubMed Central PMCID: PMC7842382.
31. Melnikova M, Wauer US, Mendus D, Hilger RA, **Oliver TG**, Mercer K, Gohlke BO, Erdmann K, Niederacher D, Neubauer H, Buderath P, Wimberger P, Kuhlmann JD, Thomale J (2020). Diphenhydramine increases the therapeutic window for platinum drugs by simultaneously sensitizing tumor cells and protecting normal cells. *Mol Oncol*, *14*(4), 686-703. PubMed PMID: 32037720; PubMed Central PMCID: PMC7138396.
32. Ireland AS, **Oliver TG** (2020). Neutrophils Create an ImpeNETrable Shield between Tumor and Cytotoxic Immune Cells. *Immunity*, *52*(5), 729-731. PubMed PMID: 32433945; PubMed Central PMCID: PMC7851833.
33. Ireland AS, Micinski AM, Kastner DW, Guo B, Wait SJ, Spainhower KB, Conley CC, Chen OS, Guthrie MR, Soltero D, Qiao Y, Huang X, Tarapcsák S, Devarakonda S, Chalishazar MD, Gertz J, Moser JC, Marth G, Puri S, Witt BL, Spike BT, **Oliver TG** (2020). MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate. *Cancer Cell*, *38*(1), 60-78.e12. PubMed PMID: 32473656; PubMed Central PMCID: PMC7393942. (Selected as *Best of Cancer Cell*, 2020).
34. Tsabar M, Mock CS, Venkatachalam V, Reyes J, Karhohs KW, **Oliver TG**, Regev A, Jambhekar A, Lahav G (2020). A Switch in p53 Dynamics Marks Cells That Escape from DSB-Induced Cell Cycle Arrest. *Cell Rep*, *32*(5), 107995. PubMed PMID: 32755587; PubMed Central PMCID: PMC7521664.
35. Huang F, Huffman KE, Wang Z, Wang X, Li K, Cai F, Yang C, Cai L, Shih TS, Zacharias LG, Chung A, Yang Q, Chalishazar MD, Ireland AS, Stewart CA, Cargill K, Girard L, Liu Y, Ni M, Xu J, Wu X, Zhu H, Drapkin B, Byers LA, **Oliver TG**, Gazdar AF, Minna JD, DeBerardinis RJ (2021). Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer. *J Clin Invest*, *131*(1). PubMed PMID: 33079728; PubMed Central PMCID: PMC7773395.
36. Olsen RR, Ireland AS, Kastner DW, Groves SM, Spainhower KB, Pozo K, Kelenis DP, Whitney CP, Guthrie MR, Wait SJ, Soltero D, Witt BL, Quaranta V, Johnson JE, **Oliver TG** (2021). ASCL1 represses a SOX9+ neural crest stem-like state in small cell lung cancer. *Genes Dev*, 35(11-12), 847-869. PubMed PMID: 34016693; PubMed Central PMCID: PMC8168563.
37. Ciampricotti M, Karakousi T, Richards AL, Quintanal-Villalonga A, Karatza A, Caeser R, Costa EA, Allaj V, Manoj P, Spainhower KB, Kombak FE, Sanchez-Rivera FJ, Jaspers JE, Zavitsanou AM, Maddalo D, Ventura A, Rideout WM, Akama-Garren EH, Jacks T, Donoghue MTA, Sen T, **Oliver TG**, Poirier JT, Papagiannakopoulos T, Rudin CM (2021). Rlf-Mycl gene fusion drives tumorigenesis and metastasis in a mouse model of small cell lung cancer. *Cancer Discov*. PubMed PMID: 34344693; PubMed Central PMCID: PMC8810895.
38. Cargill KR, Stewart CA, Park EM, Ramkumar K, Gay CM, Cardnell RJ, Wang Q, Diao L, Shen L, Fan YH, Chan WK, Lorenzi PL, **Oliver TG**, Wang J, Byers LA (2021). Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer. *Cancer Metab*, *9*(1), 33. PubMed PMID: 34556188; PubMed Central PMCID: PMC8461854.
39. Sutherland KD, Ireland AS, **Oliver TG** (2022). Killing SCLC: insights into how to target a shapeshifting tumor. *Genes Dev*, 1;36(5-6):241-258. PubMed PMID: 35318269; PubMed Central PMCID: PMC8973850.
40. Hamad SH, Montgomery SA, Simon JM, Bowman BM, Spainhower KB, Murphy RM, Knudsen ES, Fenton SE, Randell SH, Holt JR, Hayes DN, Witkiewicz AK, **Oliver TG**, Major MB, Weissman BE (2022). TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. *Oncogene*, 16. doi: 10.1038/s41388-022-02348-0. Epub ahead of print. PubMed PMID: 35577980.
41. Kelenis DP, Rodarte KE, Kollipara RK, Pozo K, Pal Choudhuri S, Spainhower KB, Wait SJ, Stastny V, **Oliver TG**, Johnson JE (2022). Inhibition of karyopherin β1-mediated nuclear import disrupts oncogenic lineage-defining transcription factor activity in small cell lung cancer. *Cancer Res*. canres.3713.2021. doi: 10.1158/0008-5472.CAN-21-3713. Epub ahead of print. PMID: 35748745.
42. Groves SM, Ildefonso GV, McAtee CO, Ozawa PMM, Ireland AS, Wasdin PT, Huang X, Qiao Y, Lim JS, Bader J, Liu Q, Simmons AJ, Lau KS, Iams WT, Hardin DP, Saff EB, Holmes WR, Tyson DR, Lovly CM, Rathmell JC, Marth G, Sage J, **Oliver TG**, Weaver AM, Quaranta V (2022). Archetype tasks link intratumoral heterogeneity to plasticity and cancer hallmarks in small cell lung cancer. *Cell Systems.* doi: 10.1016/j.cels.2022.07.006. PubMed PMID: 35981544.
43. Chen H, Gesumaria L, Park YK, **Oliver TG**, Singer DS, Ge K, Schrump DS (2023). BET inhibitors target the SCLC-N subtype of small cell lung cancer by blocking NEUROD1 transactivation. *Mol Cancer Res.* doi: 10.1158/1541-7786.MCR-22-0594. PMID: 36378541; PMCID: PMC9898120.
44. PearsallSM, Williamson SC, García Marqués, FJ Humphrey S, Hughes E, Shue YT, Bermudez A, Frese KK, Galvin M, Carter M, Priest L, Kerr A, Zhou C,**Oliver TG**, Humphries JD,Humphries MJ, Blackhall F,Cannell I, Pitteri SJ, Hannon G, Sage J, Simpson KL,Dive C (2023). Lineage plasticity in SCLC generates non-neuroendocrine cells primed for vascular mimicry. *J Thorac Oncol*. doi: 10.1016/j.jtho.2023.07.012. Epub ahead of print. PMID: 37455012.
45. Brown JM, Patel R, Smith-Fry K, Ward M, **Oliver T**, Jones KB. Genetically engineered mouse model of pleomorphic liposarcoma: Immunophenotyping and histologic characterization. Neoplasia. 2024 Feb;48:100956. doi: 10.1016/j.neo.2023.100956. Epub 2024 Jan 10. PubMed PMID: 38199172; PubMed Central PMCID: PMC10788790.
46. Oser MG, MacPherson D, **Oliver TG**, Sage J, Park KS. Genetically-engineered mouse models of small cell lung cancer: the next generation. *Oncogene*. 2024 Feb;43(7):457-469. doi: 10.1038/s41388-023-02929-7. Epub 2024 Jan 8. PMID: 38191672.
47. Finlay JB, Ireland AS, Hawgood SB, Reyes T, Ko T, Olsen RR, Abi Hachem R, Jang DW, Bell D, Chan JM, Goldstein BJ, **Oliver TG**. Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancer. *Cancer Cell.* 2024 Jun 10;42(6):1086-1105.e13. doi: 10.1016/j.ccell.2024.05.003. Epub 2024 May 23. PMID: 38788720; PMCID: PMC11186085.
48. Rodarte KE, Nir Heyman S, Guo L, Flores L, Savage TK, Villarreal J, Deng S, Xu L, Shah RB, **Oliver TG**, Johnson JE. Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1. *Cancer Res*. 2024 Nov 4;84(21):3522-3537. doi: 10.1158/0008-5472.CAN-24-1388. PMID: 39264686; PMCID: PMC11534540.
49. Huisman DH, Chatterjee D, Svoboda RA, Vieira HM, Ireland AS, Skupa S, Askew JW, Frodyma DE, Girard L, Fisher KW, Kareta MS, Minna JD, **Oliver TG**, Lewis RE. KSR2 promotes self-renewal and clonogenicity of small-cell lung carcinoma. *Mol Cancer Res*. 2025 Mar 10. doi: 10.1158/1541-7786.MCR-24-0546. Epub ahead of print. PMID: 40063515.
50. Cai L, Wu F, Zhou Q, Gao Y, Yao B, DeBerardinis RJ, Acquaah-Mensah GK, Aidinis V, Beane JE, Biswal S, Chen T, Concepcion-Crisol CP, Grüner BM, Jia D, Jones RA, Kurie JM, Lee MG, Lindahl P, Lissanu Y, Lorz C, MacPherson D, Martinelli R, Mazur PK, Mazzilli SA, Mii S, Moll HP, Moorehead RA, Morrisey EE, Ng SR, Oser MG, Pandiri AR, Powell CA, Ramadori G, Santos M, Snyder EL, Sotillo R, Su KY, Taki T, Taparra K, Tran PT, Xia Y, van Veen JE, Winslow MM, Xiao G, Rudin CM, **Oliver TG**, Xie Y, Minna JD. The Lung Cancer Autochthonous Model Gene Expression Database Enables Cross-Study Comparisons of the Transcriptomic Landscapes Across Mouse Models. *Cancer Res*. 2025 May 15;85(10):1769-1783. doi: 10.1158/0008-5472.CAN-24-1607. PMID: 40298430; PMCID: PMC12081188.
51. Ireland AS, Hawgood SB, Xie DA, Barbier MW, Lucas-Randolph S, Tyson DR, Zuo LY, Witt BL, Govindan R, Dowlati A, Moser JC, Puri S, Rudin CM, Chan JM, Elliott A, **Oliver TG**. Basal cell of origin resolves neuroendocrine-tuft lineage plasticity in cancer. bioRxiv [Preprint]. 2024 Nov 15:2024.11.13.623500. doi: 10.1101/2024.11.13.623500. PMID: 39605338; PMCID: PMC11601426. (In Press, *Nature*)

Submitted or In Revision:

1. Izzo LT, Reyes T, Meesala S, Ireland AS, Yang S, Sunil HS, Cheng XC, Tserentsoodol N, Hawgood SB, Patz Jr. EF, Witt BL, Tyson DR, O’Donnell KA, **Oliver TG**. [KLF4 promotes a KRT13+ hillock-like state in squamous lung cancer](https://www.biorxiv.org/content/10.1101/2025.03.10.641898v1). bioRxiv 2025.03.10.641898; doi: https://doi.org/10.1101/2025.03.10.641898 (*Nature Cancer*, in revision)
2. Sunil HS, Clemenceau J, Barnfather I, Nakkireddy SR, Grichuk A, Izzo L, Evers BM, Thomas L, Subramaniyan I, Li L, Putnam WT, Zhu J, Updegraff B, Minna JD, DeBerardinis RJ, Gao J, Hwang TH, **Oliver TG**, O'Donnell KA. Transmembrane Serine Protease TMPRSS11B promotes an acidified tumor microenvironment and immune suppression in lung squamous cell carcinoma. bioRxiv [Preprint]. 2025 Apr 3:2025.04.01.646727. doi: 10.1101/2025.04.01.646727. PMID: 40235980; PMCID: PMC11996519. (*EMBO Reports*, in revision)
3. Puri S, Naqash AR, Elliott A, Kerrigan K, Patel S, Seeber A, Kocher F, Uprety D, Mamdani H, Kulkarni A, Lopes G, Halmos B, Borghaei H, Akerley W, Liu SV, Korn WM, **Oliver TG**, Owonikoko TK. Multi-omic characterization of small cell lung cancer transcriptional subtypes and clinically relevant therapeutic targets. (Submitted)
4. Fatherree JP, Hippe DS, Jenkins I, Hiatt JB, Wu F, Qian W, Chen X, Simpson KL, **Oliver TG**, Dive C, Drapkin B, Randolph T, and MacPherson D. Transcriptional analyses of patient derived xenograft models reveal distinct subsets of small cell lung cancer (Submitted)
5. Govindan et al, (Submitted, NEJM)
6. Mayet A, Beatrice, P, Lécuyer D, Defruit A, Rana S, Bodac A, Demetter P, Denanglaire S, Brandão M, Berghmans T, Andris F, Goriely S, Jean Perentes JY, **Oliver TG**, Meylan E. Bcl-xL blockade targets neutrophils and synergizes with chemotherapy in lung squamous cell carcinoma” (Submitted, EMBO Mol Medicine)
7. Books: (Indicate authors or editor.)
8. Chapters in books:
9. Selected abstracts
10. Non-refereed publications: (Non-refereed publications refer to those which do not routinely use

 a system of critical review prior to publication; such articles are often solicited by the publisher.)

1. Print
2. Digital
3. Published scientific reviews for mass distribution
4. Position, and background papers
5. Non-authored publications: (Faculty member formally acknowledged in the publication for her/his contributions.)
6. Other/Letters/Editorials
7. **Oliver TG** (2013). Ovarian Stem Cells Find Their Niche. *Sci Transl Med*, *5*(177), 177ec47.
8. **Oliver TG** (2013). Dangerous Liaisons: When Two Wrongs Just Might Make a Right. *Sci Transl Med*, *5*(183), 183ec73.
9. **Oliver TG** (2013). A TWO Hit Wonder for Melanoma Treatment. *Sci Transl Med*, *5*(189), 189ec97.
10. **Oliver TG** (2013). An Inferiority Complex for Chemo. *Sci Transl Med*, *5*(195), 195ec121.
11. **Oliver TG** (2013). An Anti-Depressing Discovery for Lung Cancer Treatment. *Sci Transl Med*, *5*

(207), 207ec170.

1. **Oliver TG** (2013). Waking a Sleeping Giant...on Purpose? *Sci Transl Med*, *5*(213), 213ec196.
2. **Oliver TG** (2014). RIG-ging Biomarkers for Therapeutic Response. *Sci Transl Med*, *6*(219), 219ec11.
3. **Oliver TG** (2014). Bosom Buddies: Close Connections Between Breast and Bladder Cancer. *Sci Transl Med*, *6*(225), 225ec36.
4. Pe'er D, Ogawa S, Elhanani O, Keren L, **Oliver TG**, Wedge D (2021). Tumor heterogeneity.

*Cancer Cell*, *39*(8), 1015-1017. PubMed PMID: 34375606.

1. Weber MC, Izzo LT, **Oliver TG** (2023). Epigenetic regulators open the door to SCLC plasticity. *Cancer Res.* Sep 26. Epub ahead of print. PubMed PMID: 37756567.
2. Ireland AS, **Oliver TG** (2025). A Cancer with Some Real Nerve. *Nature* News and Views, in press.

 **Consultant appointments: (Include US government, state, private organizations, etc.)**

2024 – present Light Horse Therapeutics, Consultant

2024 – present Nuage Therapeutics, Consultant

2021 - 2023 Known Medicine, Scientific Advisory Board Member

2021 - 2022 Immunology, Inflammation, and Infectious Disease (3i) Initiative, University of Utah, Scientific Advisory Board

2020 - 2025 Lung Cancer Research Foundation (LCRF), Scientific Advisory Board Member

2020 – 2025 Lung Cancer Research Foundation (LCRF), Equity in Lung Cancer Research Task Force

 **Scholarly societies (Alpha Omega Alpha, Sigma Xi, Phi Beta Kappa; etc.)**

**Professional awards and special recognitions:**

2022 - Present Duke Science & Technology Scholar

2021 Heine H. Hansen Lectureship Award for Small Cell Lung Cancer, World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC)

2018 - 2021 William C. Rippe Award for Distinguished Research in Lung Cancer, Lung Cancer Research Foundation (LCRF)

2017 - 2019 American Lung Association, Lung Cancer Discovery Award

2013 - 2017 American Cancer Society Research Scholar Award

2013 - 2015 Damon Runyon-Rachleff Innovation Award

2012 - 2013 The V Foundation for Cancer Research, V Foundation Scholar Award

2011 Cancer Prevention and Research Institute of Texas (CPRIT) Research Award, declined

2010 - 2011 Ludwig Postdoctoral Fellowship, Massachusetts Institute of Technology

2007 - 2010 ASPET-Merck Postdoctoral Fellowship in Integrative Pharmacology

2007 Finalist, Life Sciences Research Foundation (LSRF) Postdoctoral Fellowship

2005 Faculty of 1000 Biology citation & review for Oliver, TG et al., Development, 2005

2005 Conference Travel Fellowship, Duke University (Keystone Symposium)

2004 Conference Travel Fellowship, Duke University, American Association for Cancer Research (AACR)

2004 Pfizer Education Scholarship: Travel award and poster presentation at the Keystone Symposium on Cancer and Development, Banff, Canada, 2005

2004 Molecular Cancer Biology Program nominee to represent Duke University for the Harold Weintraub Graduate Student Award

2003 - 2005 National Science Foundation (NSF) Graduate Research Fellowship

2001 B.S. in Chemistry, Summa Cum Laude with Honors

2000 - 2001 Dighton Science Scholarship, Oklahoma Baptist University

2000 University of Colorado Cancer Center (UCCC) Student Fellowship Mentor: Dr. Paul Bunn Jr., M.D., (Director)

1999 Sir Alexander Fleming Scholar, Oklahoma Medical Research Foundation Mentor: Dr. Yashige Kotake, Ph.D., Free Radical Biology & Aging Program

1997 - 2001 President's Honor Roll, Oklahoma Baptist University

1997 - 2001 Distinguished Scholar Award, Oklahoma Baptist University

1997 - 2001 Valedictorian Scholarship, Oklahoma Baptist University

**Editorial Experience**

## Editorial Boards

2023 - Present Senior Editor, *Cancer Research*

2023 - Present Consulting Editor, *Genes & Development*

2022 - Present Editorial Board, *Genes & Development*

2013 - 2014 Associate Scientific Advisor for *Science Translational Medicine*

## Ad Hoc Scientific Review Journals

## 2023 - Present Reviewer for *Journal of Clinical Investigation*

## 2022 - Present Reviewer for *Nature*

2022 - Present Reviewer for *Journal of Biological Chemistry*

2022 - Present Reviewer for *Genes & Development*

2021 - Present Reviewer for *Cell Reports Methods*

2021 - Present Reviewer for *Cell*

2020 - Present Reviewer for *Molecular Cancer Research*

2020 - Present Reviewer for *Nature Cancer*

2020 - Present Reviewer for *Sciences Advances*

2019 - Present Reviewer for *eLife*

2019 - Present Reviewer for *Cell Stem Cell*

2018 - Present Reviewer for *Molecular Cancer Therapeutics*

2018 - Present Reviewer for *Journal of Experimental Medicine*

2018 - Present Reviewer for *Translational Lung Cancer Research*

2017 - Present Reviewer for *Clinical Cancer Research*

2017 - Present Reviewer for *Cell Reports*

2016 - Present Reviewer for *Oncotarget*

2016 - Present Reviewer for *Plos Biology*

2015 - Present Reviewer for *Cancer Cell*

2015 - Present Reviewer for *Cancer Discovery*

2015 - Present Reviewer for *Nature Medicine*

2015 - Present Reviewer for *Scientific Reports*

2015 - Present Reviewer for *Disease Models & Mechanisms*

2015 - Present Reviewer for *BMC Cancer*

2013 - Present Reviewer for *Plos One*

2013 - Present Reviewer for *Oncogene*

 **Organizations and participation: (Offices held, committee assignments, etc.)**

2026 CRUK Lung Cancer Centre of Excellence External Scientific Advisory Board (SAB), London, UK

2026 CRUK National Biomarker Centre SAB invitation, London, UK (declined due to Duke travel restrictions)

2025 – Present External Advisory Board, P01, *Understanding and targeting treatment-associated lineage plasticity in cancer,* Columbia/Stanford

2025 Reviewer, Borden Scholar Review Committee, Duke University

2023 Committee Member, Department of Pharmacology and Cancer Biology Faculty Search

 2023 AACR 2023 Annual Meeting Nonclinical Models of Cancer under the Tumor Biology

Subcommittee

 2023 Reviewer, Borden Scholar Review Committee, Duke University

 2022 - 2024 Committee Member, Molecular Cancer Biology PhD Program Admissions, Duke

University

2022 – Present Moffitt Cancer Center, Lung Cancer P01 External Advisory Board (EAB)

2022 – Present Member, National Institutes of Health (NIH) Mechanisms of Cancer Therapeutics-B (MCTB) study section

2021 – 2023 Member, Known Medicine, Scientific Advisory Board

2021 Reviewer, NIH Special Emphasis Panel on National Cancer Institute (NCI) Program Project IV (P01) PAR 20-077

2021 Ad Hoc Reviewer, National Institutes of Health (NIH) Mechanisms of Cancer Therapeutics-1 (MCT1) study section

2021 Reviewer, California Institute for Regenerative Medicine (CIRM), Translational Research Program

2021 Reviewer, Boehringer Ingelheim Foundation

2021 Reviewer, V Foundation "Black\African American V Scholar Grants"

2020 - 2025 Member, Lung Cancer Research Foundation (LCRF), Equity in Lung Cancer Research Task Force

2020 - 2025 Member, Lung Cancer Research Foundation (LCRF), Scientific Advisory Board

2020 Reviewer, NIH Special Emphasis Panel on National Cancer Institute (NCI) Program Project IV (P01) PAR 20-077

2020 Reviewer, NIH Special Emphasis Panel for Cancer Biology ZRG1 OBT-K (02)

2019 Reviewer, Cancer Research United Kingdom (CRUK)

2019 Reviewer, NIH Special Emphasis Panel on Neural Regulation of Cancer PARs SEP ZRG1OBT-S (55)

2019 Reviewer, NIH Special Emphasis Panel on PAR 16-049 SCLC Consortium

2019 - 2021 Co-Chair, American Cancer Society, Tumor Biology and Genomics Study Section

2017 - 2021 Member, American Cancer Society, Tumor Biology and Genomics Study Section

2017 Ad Hoc Reviewer, American Cancer Society, Tumor Biology and Genomics

2017 - 2018 Reviewer, American Cancer Society, Institutional Research Grant (IRG)

2016 - 2022 Reviewer, Huntsman Cancer Institute, Melanoma SPORE, Internal Advisory Committee

2015 - Present Member, International Association for the Study of Lung Cancer, ID #416129

2010 - Present Member, American Association for Cancer Research, ID #101450

2015 Reviewer, Department of Defense, CDMRP, LCRP Concept Award - Pathobiology Panel

2015 - 2022 Reviewer, Medical Research Council (MRC), UK Research Council, United Kingdom

2014 - 2015 Reviewer, Children's Tumor Foundation

**External support - gifts, grants, and contracts:**

 Approximate

 PI % Effort Purpose Amount Duration

1. Past:

 Trudy G. Oliver 16% R01CA244841 $1,939,272 0920/22-05/31/25

Trudy Oliver 0% DCI Pilot $50,000 07/01/23-06/30/24

Trudy Oliver

Maria Xu (PI Fellow) 0% LCI / Mentor $25,000 07/01/23-06/30/24

Trudy G. Oliver 10% Mark Foundation $250,000 07/01/22-08/31/23

Baldomero Olivera ASPIRE Fall 21

Trudy G. Oliver, 5% U24CA213274 $45,444 02/01/19-01/31/22

 Charles Rudin, SCLC Research Consortium

 John Minna

 Trudy G. Oliver, N/A U01CA231844 $130,959 09/01/20-08/31/21

 Obi Griffith, Supplement

 Ramaswamy Govindan

 Trudy G. Oliver N/A Closer to Cure $25,000 01/01/20-12/31/20

 Gift for continued research

 Trudy G. Oliver 8% LCRF $150,000 11/01/18-10/31/20

 Trudy G. Oliver 15% R21CA21650 $358,342 12/01/17-11/30/19

 Gurkan Mollaoglu N/A F99CA223015 $65,354 09/14/17-05/02/19

 Oliver, Mentor

 Trudy G. Oliver 10% LCD-506758 $200,000 07/01/17-06/30/19

 American Lung Association

 Trudy G. Oliver 22% R01CA187457 $1,545,875 07/01/14-05/31/19

 Trudy G. Oliver 18% 124568-RSG-13-300-01 $720,000 07/01/13-06/30/17

 American Cancer Society

 Trudy G. Oliver 7% DRR-26-13 $450,000 01/01/13-06/30/16

 Damon Runyon Cancer Research Foundation

 Trudy G. Oliver N/A V Foundation for $200,000 10/01/12-09/30/14

 Cancer Research

 Trudy G. Oliver 18% W81XWH-12-1-0211 $112,125 07/01/12-06/30/13

 U.S. Department of Defense

 Trudy G. Oliver, 12% U01CA231844 $1,415,426 09/01/18-08/31/23

 Obi Griffith,

 Ramaswamy Govindan

1. Present:

Trudy G. Oliver 15% R01CA251147 $1,845,625 07/01/22-06/30/26

 Trudy G. Oliver, 10% U24CA213274 $991,250 06/24/22-05/31/27

 Charles Rudin, Renewal SCLC Research Consortium

 John Minna,

 Lauren Byers

 Abbie S. Ireland Mentor NCI F31CA275295 $142,140 09/01/22-08/31/25

 AM Pendergast 1% LCRF $149,923 12/01/23-11/30/25

Trudy Oliver 20% R01CA262134 $1,977,097 04/01/24-03/31/29

 Trudy Oliver 4% Auron Therapeutics $55,253 06/01/24-05/31/25

 Ling Cai 7% 1R01CA285336 $248,876 09/01/24-08/31/29

 Trudy G. Oliver 0% Shark Tank (DCI) $100,000 12/01/24-11/30/26

Trudy G. Oliver 0% Albert Lung (DCI) $100,000 07/01/25-06/30/26

Margaret Weber Mentor NCI F30 $140,028 2025 - present

Luke Izzo Mentor American Cancer Society $217,500 2025 - present

 Postdoctoral Fellowship

**Mentoring activities**

1. Faculty
2. Fellows, doctoral, post docs
3. Resident
4. Medical students

## Trainee Supervision

Faculty

2024 – Present Supervisor, Darren Tyson, PhD, Duke University, Research Associate Professor

2024 – Present Mentor, Laurie Graves, MD, Duke University, Medical Instructor

2023 – Present Mentor, Kaitlin Bevers MD, Duke University, Assistant Professor of Surgery

2019 - 2022 Mentor, Sonam Puri, MD, University of Utah, Assistant Professor

2017 - 2021 Mentor, Xiaoyang Zhang, PhD, University of Utah, Assistant Professor

Fellow

2023 – Present Advisor/Mentor, Lisa Earnest-Noble MD/PhD, Duke University, Otolaryngology Resident

2022 - 2025 Advisor/Mentor, Maria Mei Xu MD/PhD, Duke University, General Surgery Resident

2011 - 2013 Advisor/Mentor, Samuel Slomowitz MD, University of Utah, MD Hem/Onc Fellow

Postdoctoral

2025 – present Advisor/Mentor, Abbie Ireland, Duke University, Postdoc

2024 – present Mentoring Committee Member, Rhianna Lee, Duke University, Postdoc (Tata Lab)

2023 - present Advisor/Mentor, Luke Izzo, Duke University, Postdoc

2016 - 2017 Advisor/Mentor, Haixia Cheng, University of Utah, Postdoc

2015 Advisor/Mentor, Michelle Baladi, University of Utah, Postdoc

2013 - 2014 Supervisor, Rahul Arya, University of Utah, Postdoc

2013 - 2014 Supervisor, Chunhua Wu, University of Utah, Postdoc

2012 - 2015 Advisor/Mentor, Anandaroop Muhkopadhyay, University of Utah, Postdoc

PhD/Doctorate

2025 – Present Advisor/Mentor, Bryony Hawgood, Duke University, PhD Candidate

2024 - Present Advisor/Mentor, Aamna Abbasi, Duke University, PhD Candidate

2024 - Present Advisor/Mentor, Benjamin Hanna, Duke University, PhD Candidate

2020 - 2025 Advisor/Mentor, Abbie Ireland, Duke University, PhD Candidate (Transferred from Univ. of Utah, 2022)

2020 - 2021 Advisor/Mentor, Gabriela Fort, University of Utah, PhD Candidate (Transferred to Univ. of Utah mentor)

2019 - 2024 Advisor/Mentor, Tony Reyes, University of Utah, PhD Candidate (Remaining Utah student, but transferring to Duke as visiting student scholar, 2022)

2014 - 2019 Advisor/Mentor, Milind Chalishazar, University of Utah, PhD (completed)

 2014 - 2019 Advisor/Mentor, Gurkan Mollaoglu, University of Utah, PhD (completed)

2006 - 2014 Advisor/Mentor, Matthew Terry, University of Utah, PhD (completed) (Transfer from David Grunwald's Lab, from 2011-2014)

Medical Student

2023 - Present Advisor/Mentor, Margaret Weber, Duke University, MD/PhD Candidate

2016 Rotation Supervisor, Youna Choi, University of Utah

2016 Rotation Supervisor, Cathy Mangum, University of Utah

2013 Summer Research Supervisor, Peter Hale, University of Utah

Undergraduate

2024 – Present Supervisor, Kyra Chen, Duke University

2023 – Present Supervisor, Yurika Sakia, Duke University

2023 – Present Supervisor, Steven Yang, Duke University

2023 – Present Supervisor, Daniel Xie, Duke University

2023 - 2025 Supervisor, Lisa Zuo, Duke University

2023 Supervisor, Clara Tandar from Brown University, Duke AMGEN Scholars Program

2022 - 2025 Supervisor, Srijan Meesala, Duke University

2021 - 2022 Supervisor, Youngjae Lee, University of Utah

2021 Supervisor, Jose Herrera, University of Utah

2018 Supervisor, Greg Lee, University of Utah

2018 Supervisor, Sophia Schuman, University of Utah

2017 Supervisor, Jacqueline Lara, California State Polytechnic University Pomona

2017 - 2019 Supervisor, Sarah Wait, University of Utah

2016 - 2017 Supervisor, Yohan Paitrault, University of Utah

 2016 - 2017 Supervisor, Younjee Lee, University of Utah

2016 - 2017 Supervisor, Sangmin Jeong, University of Utah

2015 - 2016 Supervisor, Kendall Denning, University of Utah

 2015 - 2019 Supervisor, Abbie Ireland, University of Utah

2014 Supervisor, Kidus Feleke, University of Utah, Huntsman Cancer Institute Summer Internship

2013 Supervisor, Crystal Chau, University of Utah

2011 - 2012 Supervisor, Ushma Kc, University of Utah

2011 - 2012 Supervisor, Amaris Rosario, University of Utah

High School

2025 Supervisor, Aubrey Shaulis, The Peddie School, Highstown, NJ

2025 Supervisor, Oviya Murugan, North Carolina School of Science and Mathematics, Durham, NC

2021 - 2022 Advisor/Mentor, Shreya Reddy, University of Utah

2021 Advisor/Mentor, Jose Herrera, University of Utah, PathMaker Summer Research Program

2019 - 2021 Advisor/Mentor, Clara Tandar, University of Utah

2016 Advisor/Mentor, Bettsy Romo, University of Utah, PathMaker Summer Research Program

## Graduate Student Committees

## 2023 – 2024 Prelim Committee, Anita Bodac, Etienne Meylan Lab, EPFL, Switzerland

2023 Prelim Committee, Alejandra Patino, Snyder Lab, Duke University

2022 - Present Prelim/Thesis Committee, Roberto Barbier, Duke University, Pendergast Lab

2021 - 2025 Chair, Abbie Ireland, University of Utah, transferred to Duke University

2020 - 2025 Member, Brooke Gates, University of Utah, Thesis Committee, Spike Lab

2020 - 2021 Chair, Gabriela Fort, University of Utah

2020 - 2024 Chair, Tony Reyes, University of Utah

2019 - 2022 Member, Joan Cheng, University of Utah

2019 - 2023 Member, Ben Ozenberger, University of Utah, Jones Lab

2016 - 2017 Member, Pei-Yi Tai, University of Utah, Prelim and Thesis Committee, Ayer Lab

2015 - 2019 Chair, Gurkan Mollaoglu, University of Utah

2015 - 2019 Member, David Kircher, University of Utah, Holmen Lab

2015 - 2019 Chair, Milind Chalishazar, University of Utah

2015 - 2018 Member, Jamie Gardiner, University of Utah, Schiffman Lab

2015 Chair, Shelley MacNeil, University of Utah, Prelim Committee

2015 Member, Adam Gardner, University of Utah, Prelim Committee

2015 Member, Jae Hyuk Yoo, University of Utah, Thesis Committee, Li Lab

2014 - 2018 Member, Dollie LaJoie, University of Utah, Prelim Committee, Ullman Lab

2014 - 2018 Member, Karina Vasquez, University of Utah, Tantin Lab

2014 - 2017 Member, Helena Lucente, University of Utah, Engel Lab

2014 - 2015 Member, Harriet Greenlee, University of Utah, Chemistry Dept

 2012 - 2014 Chair, Matthew Terry, University of Utah

2012 - 2018 Member, Zhizhou Ye, University of Utah, Ayer Lab

2012 – 2019 Chair, Prelim Committee and Thesis Committee, David McClellan, University of Utah, Engel Lab

2012 Member, Prelim Committee, Blake Wilde, University of Utah, Ayer Lab

2012 – 2015 Member, Daria Drobysheya, University of Utah, B. Welm Lab

2012 – 2014 Member, Nader El Chaar, University of Utah, Bild Lab

2012 – 2016 Member, Matthew Velinder, University of Utah, Jones/Engel Labs

2012 Member, Prelim Committee, Susie Choi, University of Utah, Bearss Lab

2011 – 2015 Member, Shelly Sorrells, University of Utah, Jette Lab

2011 – 2015 Member, Mun Kyoung Kim, University of Utah, Topham Lab

2011 – 2013 Member, Pranav Mathur, University of Utah, Jette Lab

Additional Research/Scholarship Contributions

2024 Rotation Student Advisor – Aamna Abbasi

2024 Rotation Student Advisor – Reuben Cano

2024 Rotation Student Advisor - Benjamin Hanna

2023 Rotation Student Advisor – Nolan Bick

2023 Rotation Student Advisor – Shantelia Shook

2023 Rotation Student Advisor – Danielle Burner

2023 Rotation Student Advisor – Kira Gardner

2022 Rotation Student Advisor – Margaret Weber

2022 Rotation Student Advisor – Anna Towne

2022 Rotation Student Advisor – Meagan Luck

2021 Rotation Student Advisor - Natalie Miscik

2021 Rotation Student Advisor - Austin Peppers

2020 Rotation Student Advisor - Hannah Young

2019 Rotation Student Advisor - Yifan Wu

2019 Rotation Student Advisor - Gabriela Fort

2019 Rotation Student Advisor - Morgan Ivy

2018 Rotation Student Advisor - Victoria Krawiec

2018 Rotation Student Advisor - Pavitra Viswanath

2018 Rotation Student Advisor - Tony Reyes

2018 Rotation Student Advisor - David Freeman

2018 Rotation Student Advisor - Elliott Paine

2017 Rotation Student Advisor - Ian Cooney

2017 Rotation Student Advisor - Ben Ozenberger

2016 Rotation Student Advisor - Andrew Baessler

2015 Rotation Student Advisor - Michael Scherzer

2015 Rotation Student Advisor - Maritza Rosales

2015 Rotation Student Advisor - Kate Updike

2014 Rotation Student Advisor - Aman Makaju

2014 Rotation Student Advisor - Josh Daugherty

2014 Rotation Student Advisor - Phong Lu

2012 Rotation Student Advisor - David McClellan

2012 Rotation Student Advisor - Colin Russell

2011 Participant, HCI Cancer Center Retreat, Sundance, UT

**Education / Teaching activities (Residents, Medical students, CME)**

1. Teaching and supporting Learners See form)
2. Development of courses/educational programs
3. Development of assessment tools and methods
4. Education management/ Leadership

## Course and Curriculum Development

2024 UPGEN778, “Tumor Evolution and Heterogeneity”, Duke University. Modified course developed by Dr. Kris Wood.

2012 "Signaling in Development and Cancer." University of Utah, Graduate Student Journal Club and Grant Writing Course. Designed curriculum and co-taught with Bryan Welm, PhD

2006 "When Development Goes Awry: How Cancer Co-opts Mechanisms of Embryogenesis" MIT, Advances Undergraduate Seminar, 7.343. Co-designed and taught with Etienne Meylan, PhD (2006)

## Course Lectures

## 2024 Instructor, BIOTRAIN 720: Grant Writing for Biomedical Scientists, Duke University, School of Medicine

## 2023 Instructor, PHARM 393, Research Independent Study, Srijan Meesala, Duke University

## 2023 Instructor, BIOTRAIN 720: Grant Writing for Biomedical Scientists, Duke University, School of Medicine

## 2022 Instructor, BIOTRAIN 720: Grant Writing for Biomedical Scientists, Duke University, School of Medicine

2021 Instructor, ONCSC-6500: Molecular Mechanisms of Cancer, University of Utah, Oncological Sciences, "TP53, apoptosis, and cancer"

2021 MBIOL-6200: Critical Thinking in Research, University of Utah, Human Molecular Biology and Genetics, Paper Presentation

2021 PI, 7720: Lab Res Conferences, 3, University of Utah, School of Medicine

2021 PI, 7970: Thesis Research-Ph D, 3, University of Utah, School of Medicine

 2020 PI, 7720: Lab Res Conferences, 3, University of Utah, School of Medicine

2020 PI, 7970: Thesis Research-Ph D, 3, University of Utah, School of Medicine

2020 PI, 7720: Lab Res Conferences, 1, University of Utah, School of Medicine

2020 PI, 7970: Thesis Research-Ph D, 1, University of Utah, School of Medicine

2019 PI, 7970: Thesis Research-Ph D, 2, University of Utah, School of Medicine

2019 PI, 7720: Lab Res Conferences, 1, University of Utah, School of Medicine

2019 Instructor, ONCSC 6500: Molecular Mechanisms of Cancer, University of Utah, Oncological Sciences, "P53 and transcription factors in cancer"

2019 PI, 7970: Thesis Research-Ph D, 2, University of Utah, School of Medicine

2019 PI, 7720: Lab Res Conferences, 0, University of Utah, School of Medicine

2018 PI, 7720: Lab Res Conferences, 0, University of Utah, School of Medicine

2018 PI, 7970: Thesis Research-Ph D, 2, University of Utah, School of Medicine

2018 Instructor, MBIOL 6480: Cell Biology, 36 students, University of Utah, Human Molecular Biology and Genetics

2018 PI, 7720: Lab Res Conferences, 0, University of Utah, School of Medicine

2018 PI, 7970: Thesis Research-Ph D, 2, University of Utah, School of Medicine

2017 PI, 7720: Lab Res Conferences, 0, University of Utah, School of Medicine

2017 PI, 7970: Thesis Research-Ph D, 2, University of Utah, School of Medicine

2017 Instructor, MBIOL 6480: Cell Biology, 33 students, University of Utah, Human Molecular Biology and Genetics

2017 Instructor, ONCSC 6500: Molecular Mechanisms of Cancer, University of Utah, Oncological Sciences, "P53 signaling and tumor suppression"

2017 Developer, Molecules, Cells, and Cancer, University of Utah, Oncological Sciences, 01/23/17 2pm-3pm Signaling Cascades

2017 PI, 7970: Thesis Research-Ph D, 2, University of Utah, School of Medicine

2017 PI, 7720: Lab Res Conferences, 2, University of Utah, School of Medicine

2016 PI, 7970: Thesis Research-Ph D, 2, University of Utah, School of Medicine

2016 PI, 7720: Lab Res Conferences, 2, University of Utah, School of Medicine

2016 Developer, Molecules, Cells, and Cancer, University of Utah, Oncological Sciences, Signaling 1 - Signaling Cascades

2016 PI, 7720, 2, University of Utah, School of Medicine

2016 PI, 7970, 2, University of Utah, School of Medicine

2016 Instructor, MBIOL 6480: Cell Biology, 13 students, University of Utah, Human Molecular Biology and Genetics, Two lectures on Apoptosis.

2016 Instructor, MD ID 7310: Cells, Molecules, & Cancer, 120 students, University of Utah, Deans Office - SOM

2015 PI, 7720: Lab Res Conferences, 2, University of Utah, School of Medicine

2015 PI, 7970: Thesis Research-Ph D, 2, University of Utah, School of Medicine

2015 PI, 7720: Lab Res Conferences, 2, University of Utah, School of Medicine

2015 PI, 7970: Thesis Research-Ph D, 2, University of Utah, School of Medicine

2015 Instructor, MBIOL 6480: Cell Biology, 32 students, University of Utah, Human Molecular Biology and Genetics, Two lectures on Apoptosis

2015 Instructor, ONCSC 6500: Clin/Molec Cancer Bio, 16 students, University of Utah, Oncological Sciences

2015 Instructor, MD ID 7310: Cells, Molecules, & Cancer, 102 students, University of Utah, Deans Office - SOM

2014 Facilitator, Circulation, Respiration, and Regulation - Case Based Learning H, University of Utah, Oncological Sciences, Case Based Learning H

2014 Facilitator, Circulation, Respiration, and Regulation - Case Based Learning G, University of Utah, Oncological Sciences, Case Based Learning G

2014 Facilitator, Circulation, Respiration, and Regulation - Case Based Learning F, University of Utah, Oncological Sciences, Case Based Learning F

2014 Facilitator, Circulation, Respiration, and Regulation - Case Based Learning E, University of Utah, Oncological Sciences, Case Based Learning E

2014 Facilitator, Circulation, Respiration, and Regulation - Case Based Learning D, University of Utah, Oncological Sciences, Case Based Learning D

2014 Facilitator, Circulation, Respiration, and Regulation - Case Based Learning C, University of Utah, Oncological Sciences, Case Based Learning C

2014 Facilitator, Circulation, Respiration, and Regulation - Case Based Learning B, University of Utah, Oncological Sciences, Case Based Learning B

2014 Facilitator, Circulation, Respiration, and Regulation - Case Based Learning A, University of Utah, Oncological Sciences, Case Based Learning A

2014 Facilitator, MD ID 7360: Circ, Resp, Elimination, 101 students, University of Utah, Deans Office - SOM

2014 PI, 7720: Lab Res Conferences, 2, University of Utah, School of Medicine

2014 PI, 7970: Thesis Research-Ph D, 3, University of Utah, School of Medicine

2014 Instructor, MBIOL 6480: Cell Biology, 43 students, University of Utah, Biology, "Apoptosis"

2014 PI, 7720: Lab Res Conferences, 0, University of Utah, School of Medicine

2014 PI, 7970: Thesis Research-Ph D, 1, University of Utah, School of Medicine

2013 Integrated Case: Facilitator, Circulation, Respiration, and Regulation - Case Based Learning G, University of Utah, Oncological Sciences, Case Based Learning G

2013 Integrated Case: Facilitator, Circulation, Respiration, and Regulation - Case Based Learning F, University of Utah, Oncological Sciences, Case Based Learning F

2013 Integrated Case: Facilitator, Circulation, Respiration, and Regulation - Case Based Learning E, University of Utah, Oncological Sciences, Case Based Learning E

2013 Integrated Case: Facilitator, Circulation, Respiration, and Regulation - Case Based Learning D, University of Utah, Oncological Sciences, Case Based Learning D

2013 Integrated Case: Facilitator, Circulation, Respiration, and Regulation - Case Based Learning C, University of Utah, Oncological Sciences, Case Based Learning C

2013 Integrated Case: Facilitator, Circulation, Respiration, and Regulation - Case Based Learning B, University of Utah, Oncological Sciences, Case Based Learning B

2013 Integrated Case: Facilitator, Circulation, Respiration, and Regulation - Case Based Learning A, University of Utah, Oncological Sciences, Case Based Learning A

2013 Facilitator, MD ID 7360: Circ, Resp, Elimination, 88 students, University of Utah, Deans Office - SOM

2013 PI, 7970: Thesis Research-Ph D, 1, University of Utah, School of Medicine

2013 PI, 7720: Lab Res Conferences, 0, University of Utah, School of Medicine

2013 Instructor, ONCSC-6500: Molecular Mechanisms of Cancer, University of Utah, MD,

 "Transcription Factors in Cancer"

2013 PI, 7970: Thesis Research-Ph D, 1, University of Utah, School of Medicine

 2012 PI, 7970: Thesis Research-Ph D, 1, University of Utah, School of Medicine

 2012 PI, 7720: Lab Res Conferences, 0, University of Utah, School of Medicine

2012 PI, 7970: Thesis Research-Ph D, 1, University of Utah, School of Medicine

## Clinical Teaching

2019 Case-Based Learning (CBL) on Brain & Behavior, substitute for Dr. Alana Welm

2014 Medical School Teaching: Case-Based Learning (Pulmonary) "Circulation, Respiration, and Regulation"

2013 Medical School Teaching: Case-Based Learning (Pulmonary) "Circulation, Respiration, and Regulation"

## Small Group Teaching

2016 Faculty Mentor, Graduate Fellowship Writing Workshop for the Med2Grad program

2013 Facilitator, Cancer Biology Journal Club ONCSC-7700-003 (Tumor Resistance and Evasion Mechanisms)

2011 Facilitator, Cancer Biology Journal Club ONCSC-7700-003 (Tumor Resistance and Evasion Mechanisms)

## Educational Lectures

Didactic Lectures

2015 Molecular Cell Biology Program (Faculty Research Interest Seminar FRIS)

2015 Lecture in Biochemical Mechanisms of Signal Transduction (PH TX 7500-001)

2014 Molecular Cell Biology Program (Faculty Research Interest Seminar FRIS)

2012 Lecture, for Math Department PhD Program

2012 Molecular Cell Biology Program (Faculty Research Interest Seminar FRIS)

2011 Molecular Cell Biology Program (Faculty Research Interest Seminar FRIS)

**Invited Lectures and Presentations**

1. Named Lectures
2. Visiting Professorships
3. International Meetings
4. National Scientific Meetings (invited)
5. Instructional Courses, workshops, symposiums (National)
6. Posters (National meeting)
7. Regional presentations and posters

i. Named Lectures

2024 MD Anderson Cancer Center, John H. Blaffer Lecture Series, Houston, TX

2021 Heine H. Hansen Lectureship Award for Small Cell Lung Cancer, World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC) (Virtual due to Covid19)

2020 Oregon Health & Science University (OHSU) Knight Cancer Institute and the Department of Cell, Michael J. Hasson Lectureship for Mesothelioma, Basic and Translational Sciences Virtual Seminar Series

ii. Invited/Visiting Professor Presentations

International

2024 European Molecular Biology Laboratory, EMBL Barcelona, Science by the Beach Seminar Series

2021 Princess Margaret Research Institute Virtual Seminar Series, Toronto, ON, Canada

2021 Dana-Farber/Harvard Cancer Center, Connect: Science Virtual Seminar Series

2018 Cancer Research UK (CRUK), Manchester, England, United Kingdom

2009 University of Essen-Duisburg, Germany

National

2025 University of Texas-Southwestern Medical Center, Department of Molecular Biology, Dallas, TX

2024 Banbury, *MYC Oncoproteins for New Tumor Therapies,* Cold Spring Harbor, NY

2024 NIH SCOPE Think Tank, Rockville, MD

2024 Small Cell Lung Cancer Consortium Annual Meeting, Rockville, MD

2024 Mayo Clinic Department of Cancer Biology Seminar Series Invitation, Jacksonville, FL

2024 University of Rochester Wilmot Cancer Institute Seminar Series, Rochester, NY

2024 Fox Chase Cancer Center Distinguished Lecture Series, Philadelphia, PA

2024 UCLA Jonsson Comprehensive Cancer Center “Leaders in the Field” Seminar Series, Los Angeles, CA

2023 Northwestern University, Driskill Graduate Program Distinguished Lectures in Life Sciences, Chicago, IL

2023 Moffitt Cancer Center, Basic Science Grand Rounds, Tampa, FL

2023 University of Minnesota, The Hormel Institute, Austin, MN (declined)

2023 Purdue Center for Cancer Research Seminar Series, West Lafayette, IN

2022 Memorial Sloan Kettering Cancer Center (MSKCC), Cancer Biology & Genetics Seminar Series, New York City, NY

2022 Vanderbilt University, Frontiers in Biochemistry Seminar Series, Nashville, TN

2022 University of Pennsylvania Perelman School of Medicine, Department of Biochemistry and Biophysics “Raiziss Rounds” Seminar Series, Philadelphia, PA

2022 The University of Texas MD Anderson Cancer Center Gallick/GU Oncology Group Lab Meeting (virtual due to Covid19)

2021 Duke University, Durham, NC

2021 Beth Israel Deaconess Medical Center (BIDMC), Cancer Research Institute (CRI) virtual seminar series

2021 University of Pittsburgh Medical Center Seminar, Pittsburgh, PA

2021 Cedars-Sinai Medical Center, Cancer Immunology Club/Seminars virtual series

2021 University of Nebraska Medical Center, Eppley Institute Virtual Seminar Series

2021 McArdle Laboratory for Cancer Research, University of Wisconsin – Madison, Cancer Biology Virtual Seminar Series

2020 Fred Hutchinson Cancer Research Center, Lung SPORE Virtual Seminar Series

2020 Yale Center for Immuno-Oncology, Yale School of Medicine Virtual Seminar Series

2019 Sanford Research, Sioux Falls, SD

2019 Washington University School of Medicine, St. Louis, MO

2019 Pfizer, Pearl River, NY

2019 New York University (NYU), New York, NY

2019 Memorial Sloan Kettering Cancer Center, New York City, NY

2019 University of Michigan, Ann Arbor, MI

2018 Massachusetts Institute of Technology (MIT), Cambridge, MA

2018 University of Texas-Southwestern, Dallas, TX

2018 Duke University, Durham, NC

2017 University of Colorado, Denver, CO

2017 University of California San Francisco (UCSF), San Francisco, CA

2017 Sanford-Burnham Medical Research Institute, La Jolla, CA

2017 Icahn School of Medicine at Mount Sinai, New York, NY

2016 University of Colorado, Denver, CO

2016 Stanford University, Stanford, CA

2016 University of Texas-Southwestern, Dallas, TX

2015 University of Colorado Denver, Anschutz Medical Campus, Denver, CO

2015 University of Massachusetts, Worchester, MA

2014 Oklahoma Medical Research Foundation, Oklahoma City, OK

Local/Regional

2022 Faculty Speaker, Duke Cancer Institute Cancer Biology Retreat

2020 Huntsman Cancer Institute, Stem Cell Affinity Group Webinar

2020 Huntsman Cancer Institute, Lung Cancer Center Virtual Meeting

2020 University of Utah, Seminars in Metabolism (SIM) Virtual Presentation

2017 Huntsman Cancer Institute Second Annual Cancer Immunotherapy Conference

2016 Immunology, Inflammation & Infectious Diseases Summer Symposium 2016, Park City, UT

2015 Hem/Onc MD Fellows Meeting

## 2014 Invited Lecturer, Office of Comparative Medicine, Outreach to Kearns High School

## 2014 Invited Lecturer, Office of Comparative Medicine, Staff Outreach

2013 Bioscience PhD Programs, Annual Bioscience Symposium, Salt Lake City, UT

2013 Hem/Onc MD Fellows Meeting

2013 External Advisory Board Meeting for HCI

2013 Biochemistry Department RIP

2013 Oncological Sciences RIP

2012 Math Department RIP, invited by Fred Adler

2012 Pulmonary Division RIP

2012 Brigham Young University, Provo, UT

iii. International Meetings/Conferences/Symposia

2025 IASLC - Young Investigator Seminar Series

2025 IASLC 2025 Hot Topic Meeting: Small Cell Lung Cancer, New York

2024 NCI U24 Small Cell Lung Cancer Consortium speaker (virtual)

2023 The Mark Foundation Scientific Symposium, New York (Panelist: Curing the Deadliest Cancers)

2023 IASLC 2023 Hot Topic Meeting: Small Cell Lung Cancer, New York (Keynote Address)

2023 International German Cancer Society (AEK) Cancer Congress, Kassel, Germany (virtual)

2022 Cold Spring Harbor Laboratory (CSHL), Mechanisms & Models of Cancer meeting, Cold Spring Harbor, NY (Session Chair and Speaker)

2022 40th Sapporo International Cancer Symposium (SICS40), Japan (virtual due to Covid19)

2022 Congress of the European Association for Cancer Research, Seville, Spain (virtual)

2021 SFB 1399 Annual Virtual Meeting, Mechanisms of Drug Sensitivity and Resistance in Small Cell Lung Cancer, SCLC consortium in Germany

2021 Co-Chair with Dr. Elsa Flores, AACR Annual Meeting Virtual Mini-Symposium, “Metabolic Pathways in Cancer.”

2021 IASLC 2021 Hot Topic: Small Cell Lung Cancer Virtual Meeting

2021 Keystone eSymposia, "Precision Oncology: Translating Discovery to the Clinic" Virtual Symposia

2020 Co-Organizer and Co-Chair, *Nature* Conference- Transdisciplinary Cancer Interception: Leveraging Biology to Improve Prevention and Detection, Huntsman Cancer Institute, Salt Lake City, UT

2020 Moderator, AACR- International Association for the Study of Lung Cancer (IASLC) Conference, Panel Discussion: What to Do about Squamous Cell?, San Diego, CA

2020 Federation of American Societies for Experimental Biology (FASEB) Cell Signaling in Cancer Virtual Conference: From Mechanisms to Therapy

2020 AACR Virtual Annual Meeting II

2020 AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic, San Diego, CA

2019 AACR Annual Meeting, Atlanta, GA

2019 IASLC 2019 Small Cell Lung Cancer Meeting, New York City, NY

2019 Co-Chair/Co-Organizer, IASLC and NIH Consortium on Small Cell Lung Cancer, New York City, NY

2019 Session Chair, AACR Annual Meeting, Advances in Organ Site Research, "Small Cell Lung Cancer: A Glimmer of Light at the End of the Tunnel (AOS10)", Atlanta, GA

2018 AACR Annual Meeting, Chicago, IL

2018 AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic, San Diego, CA

2017 IASLC Small Cell Lung Cancer Workshop, New York City, NY

2016 AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic, San Diego, CA

2015 Cold Spring Harbor Asia, Development and Pathophysiology of Respiratory Systems, Suzhou, China

2015 IASLC 16th World Conference on Lung Cancer, Denver, CO

iv. National Meetings/Conferences/Symposia

2025 7th Annual END2Cancer*:* Emerging Nanotechnology and Drug Delivery Applications for Cancer Conference, Oklahoma City, OK (declined, due to Duke travel restrictions)

2022 William Guy Forbeck Research Foundation, *Neuroendocrine Cell Fate in Development and Cancer*, Pacific Grove, CA

2021 Keynote lecture, NCI National Lung Cancer SPORE Workshop (Virtual due to Covid19)

2021 NCI U24 Virtual Small Cell Lung Cancer Consortium

2020 NCI U24 Virtual Small Cell Lung Cancer Consortium

2019 MCL Steering Committee Meeting, La Jolla, CA

2019 Salk Institute Mechanisms and Models of Cancer Symposium, La Jolla, CA

2019 Cancer Metabolism and Signaling Symposium, New York Academy of Sciences,

New York, NY

2018 NCI Small Cell Lung Cancer Research Consortium Meeting, Rockville, MD

2018 AACR Special Conference on Metabolism and Cancer, New York City, NY

2018 Molecular Therapeutics of Cancer Research Meeting, Sundance, UT

2017 AACR: Advances in Modeling Cancer in Mice: Technology, Biology, and Beyond.

Orlando, FL

2017 Salk Institute Mechanisms and Models of Cancer, La Jolla, CA

2017 University of North Carolina-Chapel Hill 41st Annual Lineberger Cancer Center

Symposium, Chapel Hill, NC

2015 Salk Institute Mechanisms and Models of Cancer, La Jolla, CA

2015 Keystone Symposium on Endoderm Lineages in Development and Disease, Keystone, CO

2015 Damon Runyon Cancer Research Foundation, Accelerating Cancer Cures Symposium, New York, NY

2014 Damon Runyon-Rachleff Second Year Presentation, New York, NY

2013 Keystone Symposium on Lung Development, Cancer and Disease, Taos, NM

2010 Cold Spring Harbor, Mechanisms and Models of Cancer, Cold Spring Harbor, NY

v. Professional Community Activities

2025 LiveLung 3rd Annual Small Cell Lung Cancer Summit, Raleigh, NC; guest speaker and lab tour

2024 LiveLung 2nd Annual Small Cell Lung Cancer Summit, Raleigh, NC; guest speaker and lab tour

2022 Panel Member of Medical Alumni Council Fall Meeting, Duke University

2021 Co-Organizer, Never-Smoking NSCLC Virtual Mini-Symposium, Lung Cancer Center, Huntsman Cancer Institute, Salt Lake City, UT

2020 Guest Speaker, Lung Cancer Research Foundation (LCRF), Kites for a Cure virtual event

2016 Invited Panelist, United Nations, United Nations (UN) Women #HeForShe, Entity for Gender Equality and the Empowerment of Women

2015 Participant, American Cancer Society, Making Strides for Cancer walk

2013 Co-Chair with Dr. Bryan Welm, Cell Response and Regulation Mini-Symposium, Salt Lake City, UT

2012 Co-Chair with Dr. Cicely Jette, Cell Response and Regulation Mini-Symposium, Salt Lake City, UT

vi. Poster Presentations

2020 AACR Virtual Special Conference on Tumor Heterogeneity: From Single Cells to Clinical Impact

2019 11th AACR-JCA Joint Conference on Breakthroughs in Cancer Research: Biology to Precision Medicine, Maui, HI

2011 Bioscience Annual Symposium Poster Presentation, Salt Lake City, UT

vii. Local/Regional Presentations and Posters

2020 Illumina: Single-Cell Sequencing Virtual Symposium – Mountain West

2019 Triple III Spring 2019 Symposium, Salt Lake City, UT

2019 HCI 4th Annual Cancer Immunotherapy Conference, Salt Lake City, UT

2019 Misregulation of Developmental Pathways in Cancer, Nuclear Control Symposium, Salt Lake City, UT

2018 "MYC drives a metabolically distinct subtype of small cell lung cancer that is dependent on arginine," Seminars in Metabolism, Salt Lake City, UT

2015 "mTOR signaling in chemo-resistant small cell lung cancer", Metabolism Interest Group, Salt Lake City, UT

2015 "Metabolic reprogramming and mTOR signaling in chemotherapy resistant small cell lung cancer", Nuclear Control Program Winter Symposium, Salt Lake City, UT

2012 Cell Response and Regulation Mini-Symposium on "DNA Damage Response and Cancer Therapy", HCI, Salt Lake City, UT

2011 Multidisciplinary Cancer Research Training Program (MCRTP) Retreat, Salt Lake City, UT

2010 Koch Institute for Integrative Cancer Research, Annual Retreat, Hyannisport, MA

2009 Merck Research Laboratories, Boston, MA

2008 Colrain Meeting, Colrain, MA

2006 Lander University, Greenwood, SC

2003 Duke Pharmacology/Cancer Biology Annual Symposium, Wrightsville, NC

2001 Duke Pharmacology and Cancer Biology Annual Symposium, Wrightsville, NC

 **Clinical activity - type of practice and estimate of time commitment**:

 **Participation in academic and administrative activities of the University and Medical Center**

1. Administrative positions
2. Committees
3. Leadership positions

## i. Administrative Positions

2021 - 2022 Scientific Advisory Board, University of Utah Immunology, Inflammation, and Infectious Disease (3i) Initiative

2021 - 2022 Co-Leader, Cell Response and Regulation (CRR), Huntsman Cancer Institute (HCI)

2020 - 2022 Co-Leader, Lung Cancer Center, Huntsman Cancer Institute

ii. Committees

2025 Reviewer, Duke/Duke-NUS Collaboration Pilot Projects

2025 – present Campaign Corps and Fellows, Duke Made for This Campaign

2025 – present Basic Science Faculty Steering Committee (BSFSC), Member

2025 Host, Duke University, Pharmacology & Cancer Biology Seminar Series, Dr. Alana Welm (University of Utah, Salt Lake City, UT)

2025 Host, Duke University, Pharmacology & Cancer Biology Seminar Series, Dr. Lydia Finlay (MSKCC), New York, NY

2025 Host, Duke University, Pharmacology & Cancer Biology Seminar Series, Dr. Matthew Vander Heiden (MIT), Boston, MA

2024 Host, Developmental Stem & Cell Biology Colloquium Series, Dr. Carla Kim, Harvard Medical School, Boston, MA

2023 Host, Duke University, Pharmacology & Cancer Biology Seminar Series, Dr. Andrea Ventura, Memorial Sloan Kettering Cancer Center, New York, NY

2023 Host, Duke University, Pharmacology & Cancer Biology Seminar Series, Dr. Gina DeNicola, Moffitt Cancer Center, Tampa, FL

2023 - present Pharmacology and Cancer Biology Faculty Search Committee, Duke University

2022 – 2024 Molecular Cancer Biology PhD Program Admissions Committee, Duke University

2021 Examiner, Bioscience PhD Programs, Molecular Biology PhD Program Capstone examiner April 29- May 5, 2021

2021 Host, Huntsman Cancer Institute, HCI Seminar Series, Dr. Miriam Merad (The Tisch Cancer Institute at Mount Sinai School of Medicine, New York City, NY)

2021 Host, Huntsman Cancer Institute, HCI Seminar Series, Dr. Owen N. Witte (UCLA David Geffen School of Medicine, Los Angeles, CA)

## 2021 Member, Research Misconduct Investigation Committee, ID# R01-1-2021

2021 Host, Oncological Sciences, Dr. Hua Zhang, (Perlmutter Cancer Center, New York University School of Medicine)

2020 - 2022 Member, Rising Stars in Cancer Biology Seminar Series

2020 - 2022 Member, Huntsman Cancer Institute, Human Rights Campaign (HRC) Healthcare Equality Index Committee

2020 Host, Bioscience PhD Programs, Annual Bioscience Symposium, Dr. Johanna Joyce (University of Lausanne, Lausanne, Switzerland)

2020 Examiner, Bioscience PhD Programs, Molecular Biology PhD Program Capstone examiner April 23-27, 2020

2020 Co-Organizer & Co-Chair, Huntsman Cancer Institute, Nature Conference- Transdisciplinary Cancer Interception: Leveraging Biology to Improve Prevention and Detection

2020 Host, Huntsman Cancer Institute, HCI Seminar Series, Dr. Mikala Egeblad (Cold Spring Harbor Laboratory, New York)

2019 - 2022 Member, Department of Oncological Sciences Executive Committee

## 2019 Faculty Mentor, Grant Writing Academy, Deer Valley, UT

2019 Host, Oncological Sciences, Dr. Jane Johnson, Visiting Scholar, (UT Southwestern)

2019 Host, Oncological Sciences, Dr. Tom Wilkie, Visiting Scholar, (UT Southwestern)

2018 - 2021 Member, Huntsman Cancer Institute, Clinical Research Executive Committee (CREC)

2018 Host, Oncological Sciences, Dr. Etienne Meylan (Swiss Institute for Experimental Cancer Research (ISREC), Lausanne, Switzerland)

2017 - 2018 Co-Chair, Department of Oncological Sciences, Junior Faculty Search Committee

## 2017 Faculty Mentor, Grant Writing Academy, Deer Valley, UT

2017 Host, Oncological Sciences, Dr. Triparna Sen, Visiting Scientist, (MD Anderson Cancer Center)

2017 Host, Oncological Sciences, Dr. Jane Johnson (UT Southwestern)

2017 Host, Oncological Sciences, Dr. Kevin Freeman (St. Jude Children's Research Hospital, Memphis, TN)

2016 - 2018 Member, University of Utah Health, Office of Health Equity and Inclusion Committee

 2016 - 2017 Co-Leader, HCI Strategic Planning Working Group, Therapeutic Innovation

2016 Organizer & Host, Cell Response and Regulation Program, Dr. Adi Gazdar (UT Southwestern)

2015 Host, Oncological Sciences, Dr. Kate Sutherland (Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia)

2015 Host, Oncological Sciences, Dr. Julien Sage (Stanford University Medical Center)

2015 Host, Huntsman Cancer Institute, HCI Seminar Series, Dr. Laura Attardi (Stanford)

 2015 Host, Huntsman Cancer Institute, HCI Seminar Series, Dr. Gerard Evan (University of Cambridge)

2014 - 2022 HCI Senior Faculty Search Committee

2014 - 2018 Phase IV Huntsman Cancer Institute Building Planning Committee, Vivarium

2014 - 2017 Chemical Biology Faculty Search Committee, Department of Biochemistry and USTAR

2014 Host, School of Medicine, Seminar Series Host for Dr. Andrea McClatchey (Harvard)

2014 Host, Huntsman Cancer Institute, HCI Seminar Series Host for Dr. Geoff Wahl (Salk Institute)

2013 - 2016 Molecular Biology PhD Program Admissions Committee

2013 - 2014 Molecular Biology PhD Program Academic Advising Committee

2013 Host, Huntsman Cancer Institute, Seminar Series Host for Dr. Inder Verma (Salk Institute)

2013 Organizer & Host, Cell Response and Regulation Program, Seminar Committee, Co-Chair, Host of Dr. David Ornitz (Washington University in St. Louis)

2013 Host, Huntsman Cancer Institute, Seminar Series Host, Dr. Rob Wechler-Reya (Sanford Burnham)

 2012 - 2022 HCI Micro-CT Small Animal Imaging Instrument Manager

2012 - 2015 HCI Seminar Series Committee, Member

2012 - 2014 Poster Judge, Bioscience PhD Programs, Bioscience Symposium

2012 Host, School of Medicine, Seminar Series Host, Dr. Gigi Lozano (MD Anderson)

2012 Host, Huntsman Cancer Institute, Seminar Series Host, Dr. Galit Lahav (Harvard)

2011 - 2022 Member, Cell Response and Regulation, Huntsman Cancer Institute

**INTELLECTUAL PROPERTY**

**Patents**

08/17/2021 Trudy G. Oliver, Martin Sos, Rob Wechsler-Reya (08/17/2021). U-6240 “MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition”; Awarded 09/21/2021, US11,124,841B2

10/05/2020 (Pending). U-7055 “Patient-Derived Xenograft (PDX) Models of Lung Cancer”

05/22/2013 (Pending). U-5608 “Creation of Mouse Model of Squamous Cell Lung Cancer”

Personal Information

Faculty members’ preferred familiar name: \_\_\_\_Trudy\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Home address: \_\_\_(current) 4902 Mill Hill Ln, Chapel Hill, NC 27517 \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Home Phone # \_617-460-7487 (cell)\_\_\_\_\_\_\_\_\_\_\_\_\_

Email address:\_\_\_\_tgo@duke.edu\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_